EvolveImmune’s pioneering strategy to tackle key therapeutic challenges in cancer immunotherapy has been recognized by Sally Church of the Biotech Strategy Blog. EVOLVE’s unique, integrated CD2 co-stimulation continues to empower new insights into anti-tumor immunity. Please click the link below to access a PDF version of the article.
And to access the article on the blog the web address is listed below
A window into the future of IO | Biotech Strategy Blog